PureTech Health counts several prominent institutional investment management firms, specialized life science venture funds, global asset managers, and corporate insiders among its major shareholders. Because the company operates as a clinical-stage biotherapeutic developer with public listings, its institutional registry includes major international financial institutions and specialized healthcare funds that support its hub-and-spoke model of drug discovery and venture incubation.